Journal of Clinical Oncology - ASCO Publications
WEBSep 9, 2024 · A world where cancer is prevented or cured. Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a …
ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
WEBFor more information on these guidelines, including information about planned guidelines, please access the ASCO.org guidelines page. Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care. Guidelines can address specific clinical situations (disease-oriented) or use of approved medical ...
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
WEBOct 17, 2022 · Perioperative chemotherapy is recommended for a total preoperative and postoperative duration of 6 months, on the basis of total duration of chemotherapy in the EORTC 40983 trial. 64. Table 10. Perioperative Chemotherapy Versus Surgery Alone for Patients With Liver Metastases From Colorectal Cancer 22. Open in viewer.
Recent Advances in the Management of Metastatic Prostate Cancer
WEBSep 2, 2021 · Management of metastatic prostate cancer has undergone a revolution over the past decade with the introduction of several novel agents and repurposing of others. Several clinical trials reported improved outcomes with the intensification of androgen deprivation therapy by the addition of docetaxel chemotherapy or novel hormonal agents (abiraterone, enzalutamide, or apalutamide) in the ...
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
WEBPURPOSE To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. RECOMMENDATIONS Surgery is a reasonable option for patients ...
Gastroesophageal Junction Adenocarcinoma: Is There an Optimal ...
WEBMay 17, 2019 · The incidence of gastroesophageal junction (GEJ) adenocarcinomas has been rising over the past few decades, creating a need for effective therapeutic strategies. Treatment of locally advanced GEJ tumors, in particular, present a unique challenge because these tumors have generally been approached as either esophageal or gastric cancers, and thus optimal preoperative management remains ...
ASCO Annual Meeting | ASCO Daily News
WEBJune 19, 2024. Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers. Breast Cancer.
Antiemetics: ASCO Guideline Update | Journal of Clinical Oncology
WEBJul 13, 2020 · The first ASCO guideline for antiemetics was published in 1999, 1 with updates in 2006, 2 2011, 3 2015, 4 and 2017. 5 This update of the 2017 guideline provides guidance on the use of dexamethasone as a prophylactic antiemetic in patients receiving CPIs. This guideline update addresses programmed death-1 (PD-1), programmed death 1–ligand (PD ...
Management of Stage III Non–Small-Cell Lung Cancer: ASCO …
WEBDec 22, 2021 · PURPOSE To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic ...
Updated Diagnostic Criteria and Staging System for Multiple …
WEBMay 19, 2016 · The diagnosis of MM requires 10% or more clonal plasma cells on bone marrow examination or a biopsy-proven plasmacytoma plus the presence of one or more myeloma-defining events. 10 Myeloma-defining events include the presence of one or more CRAB features, or one or more biomarkers of malignancy. The three biomarkers included in the definition of MM are associated with an approximately 80% risk ...
Skip to content